Comparison between Accel Frontline IPO and JHS Svendgaard Laboratories IPO.
Accel Frontline IPO is a Mainboard Bookbuilding IPO proposed to list at BSE, NSE while JHS Svendgaard Laboratories IPO is a Mainboard Bookbuilding proposed to list at BSE, NSE.
The total issue size of Accel Frontline IPO is up to ₹42.27 Cr whereas the issue size of the JHS Svendgaard Laboratories IPO is up to ₹35.96 Cr. The final issue price of Accel Frontline IPO is ₹75.00 per share and of JHS Svendgaard Laboratories IPO is ₹58.00 per share.
| Accel Frontline IPO | JHS Svendgaard Laboratories IPO | |
|---|---|---|
| Face Value | ₹10 per share | ₹10 per share |
| Issue Price (Lower) | ₹75.00 per share | ₹49.00 per share |
| Issue Price (Upper) | ₹90.00 per share | ₹58.00 per share |
| Issue Price (Final) | ₹75.00 per share | ₹58.00 per share |
| Discount (Retail) | ||
| Discount (Employee) | ||
| Market Lot Size | 70 shares | |
| Fresh Issue Size | 51,75,667 shares | 62,00,332 shares |
| Fresh Issue Size (Amount) | up to ₹38.82 Cr | up to ₹35.96 Cr |
| OFS Issue Size | 4,60,283 shares | 0 shares |
| OFS Issue Size (Amount) | up to ₹3.45 Cr | up to ₹0.00 Cr |
| Issue Size Total | 56,35,950 shares | 62,00,332 shares |
| Issue Size Total (Amount) | up to ₹42.27 Cr | up to ₹35.96 Cr |
Accel Frontline IPO opens on Sep 28, 2006, while JHS Svendgaard Laboratories IPO opens on Sep 26, 2006. The closing date of Accel Frontline IPO and JHS Svendgaard Laboratories IPO is Oct 05, 2006, and Oct 04, 2006, respectively.
| Accel Frontline IPO | JHS Svendgaard Laboratories IPO | |
|---|---|---|
| Anchor Bid Date | ||
| Issue Open | Sep 28, 2006 | Sep 26, 2006 |
| Issue Close | Oct 05, 2006 | Oct 04, 2006 |
| Basis Of Allotment (Tentative) | ||
| Initiation of Refunds (Tentative) | ||
| Credit of Share (Tentative) | ||
| Listing date (Tentative) | Oct 30, 2006 | Oct 21, 2006 |
| Anchor Lockin End date 1 | ||
| Anchor Lockin End date 2 |
Accel Frontline IPO P/E ratio is , as compared to JHS Svendgaard Laboratories IPO P/E ratio of .
| Accel Frontline IPO | JHS Svendgaard Laboratories IPO | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Financials | Company Financials (Restated Consolidated)
| Company Financials (Restated Consolidated)
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Promoter Shareholding (Pre-Issue) | 93.43 | 97.71 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Promoter Shareholding (Post-Issue) | 71.95 | 49.35 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| P/E Ratio | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Market Cap | ₹72.50 Cr. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ROE | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ROCE | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Debt/Equity | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| EPS | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| RoNW | 15.86 | 23.45 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
In the Accel Frontline IPO Retail Individual Investors (RII) are offered 19,72,582 shares while in JHS Svendgaard Laboratories IPO retail investors are offered 19,72,582 shares. Qualified Institutional Buyers (QIB) are offered 28,17,975 shares in Accel Frontline IPO and 31,00,000 shares in JHS Svendgaard Laboratories IPO.
| Accel Frontline IPO | JHS Svendgaard Laboratories IPO | |
|---|---|---|
| Anchor Investor Reservation | 0 shares | |
| Market Maker Reservation | 0 shares | |
| QIB | 28,17,975 shares | 31,00,000 shares |
| NII | 8,45,393 shares | 9,30,000 shares |
| RII | 19,72,582 shares | 21,70,000 shares |
| Employee | 0 shares | |
| Others | ||
| Total | 56,35,950 shares | 62,00,000 shares |
Accel Frontline IPO subscribed in total, whereas JHS Svendgaard Laboratories IPO subscribed .
